Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor–naive patients with mIDH1(R132) relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib monotherapy 150 mg twice daily in the p...

Descripción completa

Detalles Bibliográficos
Autores principales: de Botton, Stéphane, Fenaux, Pierre, Yee, Karen, Récher, Christian, Wei, Andrew H., Montesinos, Pau, Taussig, David C., Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Khwaja, Asim, Legrand, Ollivier, Peterlin, Pierre, Arnan, Montserrat, Blum, William, Cilloni, Daniela, Hiwase, Devendra K., Jurcic, Joseph G., Krauter, Jürgen, Thomas, Xavier, Watts, Justin M., Yang, Jay, Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Barrett, Emma, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362540/
https://www.ncbi.nlm.nih.gov/pubmed/36724515
http://dx.doi.org/10.1182/bloodadvances.2022009411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362540/
https://www.ncbi.nlm.nih.gov/pubmed/36724515
http://dx.doi.org/10.1182/bloodadvances.2022009411

Ejemplares similares